Philippe Marambaud
  • E-mail :[email]
  • Phone : 001 516 562 3492
  • Location : Manhasset, New York, États-Unis
Last update 2016-12-22 12:53:46.302

Philippe Marambaud PhD

Course and current status

1995 - 1998: PhD in Biology, Université de Nice Sophia Antipolis, IPMC - Sophia Antipolis, Valbonne, France (Advisor: Dr. Frédéric Checler)

1998 - 2000: Post-doctoral Fellow, Dept. of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA (Advisor: Dr. Nikolaos K Robakis)

2001 - 2002: Instructor, Dept. of Psychiatry, Mount Sinai School of Medicine, New York, NY

2003 - 2004: Assistant Professor (Research), Dept. of Psychiatry, Mount Sinai School of Medicine, New York, NY

2004 - 2011: Assistant Professor (Clinical), Dept. of Pathology, Albert Einstein College of Medicine, Bronx, NY

2005 - 2010: Assistant Investigator, The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY

2005 - present: Senior Research Scientist, Director, Laboratory of Memory Disorders, The Litwin-Zucker Research Center for the Study of Alzheimer's Disease, The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY

2010 - present: Associate Professor, The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY

Scientific summary

ALZHEIMER DISEASE
My research focuses on the molecular basis of neuronal degeneration in Alzheimer's disease. My laboratory studies the early biochemical changes leading to the formation of two classic lesions of the Alzheimer brain, the senile plaques and the neurofibrillary tangles. We currently focus our attention on the role played by the ion channel CALHM1 and the kinase AMPK in the pathogenesis of this disease.

HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Since 2015, my laboratory has significantly expanded its activities to include programs aimed at studying the vascular disease called hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome. In cell and mouse models for this disease, we seek to increase our understanding of the molecular basis of HHT, but also to identify disease-modifying interventions.

KEY PUBLICATIONS
1. Baki L#, Marambaud P#, Efthimiopoulos S, Georgakopoulos A, Wen P, Cui W, Ozawa M, Friedrich Jr VL, Robakis NK. Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits epithelial cadherin/p120 association, and regulates stability and function of the cadherin adhesion complex. Proc Natl Acad Sci USA 2001 Feb 27;98(5):2381-6. #Contributed equally to this work.

2. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis NK. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002 Apr 15;21(8):1948-56.

3. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK. A CBP-binding transcriptional repressor produced by the PS1/γ-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003, 114, 635-645.

4. Marambaud P*, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005, 280: 37377-82.

5. Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P*. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 2008 Jun 27;133(7):1149-61.

6. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P*. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010 Mar 19;285(12):9100-13.

7. Vingtdeux V, Davies P, Dickson DW, Marambaud P*. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol 2011 Mar;121(3):337-49.

8. Dreses-Werringloer U, Vingtdeux V, Zhao H, Chandakkar P, Davies P, Marambaud P. CALHM1 controls Ca2+-dependent MEK/ERK/RSK/MSK signaling in neurons. J Cell Sci 2013 Mar 1;126(Pt 5):1199-206.

9. Taruno A, Vingtdeux V, Ohmoto M, Ma Z, Dvoryanchikov G, Li A, Adrien L, Zhao H, Leung S, Abernethy M, Koppel K, Davies P, Civan M, Chaudhari N, Matsumoto H, Hellekant G, Tordoff M, Marambaud P#, Foskett JK# (#co-senior/co-corresponding authors). CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature 2013, 495(7440):223-6.

10. Vingtdeux V, Chang EH, Frattini SA, Zhao H, Chandakkar P, Adrien L, Strohl JJ, Gibson EL, Ohmoto M, Matsumoto I, Huerta PT, Marambaud P. CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice. Sci Rep 2016 Apr 12;6:24250.


Image d’exemple